| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00008571-200204000-00010 |
| P698 | PubMed publication ID | 11927841 |
| P50 | author | Craig R. Lee | Q56883997 |
| P2093 | author name string | John A Pieper | |
| Joyce A Goldstein | |||
| P433 | issue | 3 | |
| P304 | page(s) | 251-263 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data | |
| P478 | volume | 12 |
| Q34797671 | A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? |
| Q28468645 | A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9 |
| Q28217697 | A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement |
| Q35827860 | A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. |
| Q28210138 | A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma |
| Q61953161 | A simple method for the detection of CYP2C9 polymorphisms: nested allele-specific multiplex polymerase chain reaction |
| Q38303416 | Advances in pharmacotherapy for the treatment of gout |
| Q92509688 | Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects |
| Q35826938 | Allele and genotype frequencies of CYP2C9 in a Korean population |
| Q43759147 | Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population |
| Q44593135 | Allele and genotype frequency of CYP2C9 in Tamilnadu population |
| Q34147587 | An integrative method for scoring candidate genes from association studies: application to warfarin dosing |
| Q42701943 | Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR. |
| Q36412046 | Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray |
| Q90296087 | Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning |
| Q36655034 | Antimicrobial-associated QT interval prolongation: pointes of interest |
| Q85888644 | Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure |
| Q24621760 | Applications of CYP450 testing in the clinical setting |
| Q44828003 | Association between the CYP2C9 polymorphism and the drug metabolism phenotype |
| Q37325319 | Association of CYP2C9*2 with bosentan-induced liver injury |
| Q46908254 | Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q79227006 | Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants |
| Q40267083 | CYP1A1m1 and CYP2C9*2 and *3 polymorphism and risk to develop ARV-associated hepatotoxicity and its severity |
| Q84766043 | CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects |
| Q54684440 | CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. |
| Q34394876 | CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis |
| Q44849911 | CYP2C9 genetic polymorphisms and warfarin |
| Q44936830 | CYP2C9 genetic variants and losartan oxidation in a Turkish population. |
| Q33984240 | CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases |
| Q34426453 | CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. |
| Q38513684 | CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects |
| Q35913092 | CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. |
| Q36440202 | CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study |
| Q46645176 | CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population |
| Q34744094 | CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. |
| Q46820522 | Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. |
| Q35830941 | Celecoxib pathways: pharmacokinetics and pharmacodynamics |
| Q34238267 | Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis |
| Q90731111 | Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications |
| Q30939373 | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population |
| Q88869815 | Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction |
| Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
| Q90441385 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs |
| Q38961083 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update |
| Q27008360 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing |
| Q34389432 | Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing |
| Q34435116 | Clinical pharmacokinetics of losartan |
| Q35778961 | Clinical pharmacology: special safety considerations in drug development and pharmacovigilance |
| Q35594567 | Clinical relevance of genetic polymorphisms in the human CYP2C9 gene |
| Q39065445 | Combination analysis in genetic polymorphisms of drug-metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population |
| Q46888030 | Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients |
| Q90667673 | Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation |
| Q38074715 | Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels |
| Q36545011 | Contribution of CYP2C9 to variability in vitamin K antagonist metabolism |
| Q42791847 | Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations |
| Q58558658 | Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients |
| Q36492939 | Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population |
| Q51468608 | Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. |
| Q42071895 | Cytochrome P450 2C9 gene polymorphism in phenytoin induced gingival enlargement: A case report |
| Q44815207 | Cytochrome P450 2C9 phenotyping using low-dose tolbutamide |
| Q37219846 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma |
| Q37691210 | Cytochrome P450 2C9-CYP2C9. |
| Q36960539 | Cytochrome P450 reaction-phenotyping: an industrial perspective |
| Q44431094 | Cytochrome P4502C9 activity in end‐stage renal disease |
| Q28553076 | Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data |
| Q46655061 | Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers |
| Q35846894 | Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator |
| Q37841723 | Developmental pharmacogenomics |
| Q35876954 | Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms |
| Q44405606 | Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes |
| Q36732076 | Differential genotype dependent inhibition of CYP2C9 in humans |
| Q34581729 | Diplotypes of CYP2C9 gene is associated with coronary artery disease in the Xinjiang Han population for women in China |
| Q36205082 | Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method |
| Q37715233 | Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective |
| Q39732661 | Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations |
| Q56391087 | Dose calculation of anticancer drugs |
| Q36061821 | Drug bioactivation, covalent binding to target proteins and toxicity relevance |
| Q36283721 | Drug-drug interactions of antifungal agents and implications for patient care |
| Q34154939 | Drug-gene interactions: inherent variability in drug maintenance dose requirements |
| Q38433018 | Drug-induced gingival overgrowth: the genetic dimension |
| Q52777825 | Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. |
| Q47305319 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis |
| Q50441616 | Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers. |
| Q46120062 | Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers |
| Q51058603 | Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. |
| Q51663926 | Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. |
| Q42018917 | Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam |
| Q54172975 | Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. |
| Q24651117 | Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide |
| Q51275882 | Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes. |
| Q42101761 | Effects of some commonly used Saudi folk herbal medications on the metabolic activity of CYP2C9 in human liver microsomes |
| Q53338812 | Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans. |
| Q37264555 | Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics |
| Q55379283 | Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine. |
| Q36986803 | Evaluation of cytochrome P450 2C9 activity in normal, healthy, adult Western Indian population by both phenotyping and genotyping |
| Q41958385 | Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers |
| Q46679743 | Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients |
| Q39514336 | Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population |
| Q39232150 | Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics |
| Q38984342 | Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen |
| Q54092302 | Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan. |
| Q41096175 | Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group |
| Q58581001 | Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population |
| Q46619481 | Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study |
| Q44038170 | Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population |
| Q35110430 | Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population |
| Q44760870 | Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study |
| Q36052505 | Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI) |
| Q35825569 | Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations |
| Q45294002 | Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo |
| Q35753607 | Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers |
| Q36410400 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer |
| Q33936573 | Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin |
| Q35046080 | Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use |
| Q37160420 | Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin |
| Q40849334 | Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices |
| Q49142379 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. |
| Q36344243 | Genetics of drug resistance |
| Q34934523 | Genetics of warfarin sensitivity in an emergency department population with thromboembolic. |
| Q48129186 | Genistein Exposure Interferes with Pharmacokinetics of Celecoxib in SD Male Rats by UPLC-MS/MS. |
| Q45058224 | Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region |
| Q36624080 | Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy |
| Q73466818 | Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q38103593 | Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer |
| Q35102211 | Implications of pharmacogenetics for individualizing drug treatment and for study design |
| Q46447916 | Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy |
| Q44644004 | Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor |
| Q37195550 | Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin |
| Q44642230 | Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes |
| Q42985549 | Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients |
| Q46433362 | Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose |
| Q46298744 | Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. |
| Q45937530 | Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. |
| Q46185931 | Inhibitory Interactions of Aspalathus linearis (Rooibos) Extracts and Compounds, Aspalathin and Z-2-(β-d-Glucopyranosyloxy)-3-phenylpropenoic Acid, on Cytochromes Metabolizing Hypoglycemic and Hypolipidemic Drugs. |
| Q46918393 | Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients |
| Q36007599 | Interaction of warfarin with drugs, natural substances, and foods |
| Q36745175 | Interaction potential between cranberry juice and warfarin |
| Q34649093 | Interactions between urinary 4-tert-octylphenol levels and metabolism enzyme gene variants on idiopathic male infertility |
| Q46250024 | Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. |
| Q73706040 | Leukotriene antagonists |
| Q44897880 | Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers |
| Q51392151 | Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy. |
| Q44487379 | Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals |
| Q46975102 | Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. |
| Q37037876 | Medical Comorbidity and Complications |
| Q36360811 | Metabolism and transport of oxazaphosphorines and the clinical implications |
| Q48323326 | Metabolism of 7-ethoxycoumarin, flavanone and steroids by cytochrome P450 2C9 variants |
| Q50263760 | Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. |
| Q99616722 | Modulation of CYP2C9 activity and hydrogen peroxide production by cytochrome b5 |
| Q36402212 | Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics |
| Q35689076 | Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability |
| Q36699888 | Novel CYP2C9 promoter variants and assessment of their impact on gene expression |
| Q60935364 | OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide |
| Q36417380 | Parsing interindividual drug variability: an emerging role for systems pharmacology |
| Q42758765 | Personalized drug therapy; the genome, the chip and the physician |
| Q46075812 | Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing |
| Q57226195 | Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy |
| Q83984019 | Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population |
| Q37087348 | Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin |
| Q35038052 | Pharmacogenetics in drug regulation: promise, potential and pitfalls |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q35204081 | Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin |
| Q35127786 | Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine |
| Q57918700 | Pharmacogenetics of Sulfonylureas |
| Q37205954 | Pharmacogenetics of analgesics: toward the individualization of prescription |
| Q36543128 | Pharmacogenetics of chronic cardiovascular drugs: applications and implications |
| Q38050316 | Pharmacogenetics of nonsteroidal anti-inflammatory drugs |
| Q36656419 | Pharmacogenetics of target genes across the warfarin pharmacological pathway |
| Q35067187 | Pharmacogenetics of the major polymorphic metabolizing enzymes. |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q57179825 | Pharmacogenomics Aspect of Warfarin Therapy |
| Q36105822 | Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q28171051 | Pharmacogenomics and drug response in cardiovascular disorders |
| Q39084353 | Pharmacogenomics in epilepsy. |
| Q47570862 | Pharmacogenomics of CYP2C9: Functional and Clinical Considerations |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q60046975 | Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit |
| Q42359900 | Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers |
| Q34343308 | Phenobarbital for the treatment of epilepsy in the 21st century: a critical review |
| Q42432400 | Phenytoin Hypersensitivity: It's Time for Some Individuality |
| Q46230625 | Phenytoin toxicity due to genetic polymorphism |
| Q90636240 | Physicians' Attitudes and Ethical Obligations to Pharmacogenetic Testing |
| Q47738894 | Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. |
| Q44881633 | Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects |
| Q83308344 | Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9 |
| Q35859052 | Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds |
| Q33392997 | Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data |
| Q46043535 | Prevalence of CYP2C9 polymorphisms in the south of Europe. |
| Q44983984 | QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. |
| Q34024630 | Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. |
| Q46049613 | Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers |
| Q44607096 | Reproducibility over time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9 genotypes |
| Q44226094 | Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. |
| Q42098029 | Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects |
| Q36441521 | Role of cytochrome P450 genotype in the steps toward personalized drug therapy |
| Q44989488 | Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone |
| Q37733582 | Role of warfarin pharmacogenetic testing in clinical practice |
| Q43151688 | Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. |
| Q45869049 | Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. |
| Q37160370 | Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? |
| Q81010870 | Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis |
| Q92156926 | Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components |
| Q30396630 | Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. |
| Q89538069 | The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children |
| Q92157361 | The Role of Pharmacogenetics in Management of Cardiovascular Disease |
| Q44649926 | The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children |
| Q35827277 | The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. |
| Q43257046 | The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects |
| Q35827919 | The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects |
| Q89959099 | The increasing challenge of the possible impact of ethnicity on psychopharmacology |
| Q37489316 | The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis |
| Q36192806 | The pharmacogenetics of coumarin therapy. |
| Q46878607 | The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics |
| Q89500213 | The relationships between cytochromes P450 and H2O2: Production, reaction, and inhibition |
| Q33978913 | The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution |
| Q33597311 | The transcriptional regulation of the human CYP2C genes |
| Q41118521 | The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example |
| Q44395024 | Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype |
| Q44273797 | Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans |
| Q35873687 | Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes |
| Q37945308 | Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. |
| Q28539428 | Understanding a substrate's product regioselectivity in a family of enzymes: a case study of acetaminophen binding in cytochrome P450s |
| Q30978916 | Use of genetic data to guide therapy in arterial disease |
| Q42707118 | VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. |
| Q28476502 | VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker |
| Q46982015 | Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy |
| Q36729040 | Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
| Q81887452 | Warfarin pharmacogenetics |
| Q34746605 | Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. |
| Q27027304 | Warfarin pharmacogenetics: does more accurate dosing benefit patients? |
| Q37205695 | Warfarin pharmacogenomics in children |
Search more.